Cargando…
Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
Autores principales: | Wambier, Carlos G., Nau, Gerard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Association of Urology. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864079/ https://www.ncbi.nlm.nih.gov/pubmed/35304000 http://dx.doi.org/10.1016/j.eururo.2022.01.049 |
Ejemplares similares
-
Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293
por: Dong, Chen, et al.
Publicado: (2022) -
Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
por: Welen, Karin, et al.
Publicado: (2022) -
Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients
por: Welén, Karin, et al.
Publicado: (2022) -
A Conversation with Karin Öberg
por: McElvery, Raleigh
Publicado: (2021) -
First person – Karin Tuschl
Publicado: (2022)